ACYCLOVIR Drug Patent Profile
✉ Email this page to a colleague
When do Acyclovir patents expire, and what generic alternatives are available?
Acyclovir is a drug marketed by Actavis Elizabeth, Adaptis, Apotex, Aurobindo Pharma Usa, Cadila, Cadila Pharms Ltd, Carlsbad Technology, Chartwell Molecules, Heritage, Ivax Sub Teva Pharms, Lek Pharm, Mylan, Ranbaxy, Roxane, Strides Pharma, Teva, Teva Pharms, Watson Labs, Yiling, Alembic, Amneal, Padagis Israel, Taro, Zydus Lifesciences, Abbvie, Amneal Pharms, Anda Repository, Chartwell Rx, Cipla, Cosette, Fougera Pharms Inc, Glenmark Speclt, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Torrent, Xiromed, Actavis Mid Atlantic, Aurobindo Pharma, Hetero Labs Ltd Iii, Hikma, MSN, Novitium Pharma, Rubicon, Vistapharm Llc, Apotex Inc, Carlsbad, Hetero Labs Ltd V, Square Pharms, Sun Pharm Inds Ltd, Zydus Pharms, Eurohlth Intl Sarl, Apothecon, Chartwell Injectable, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Norvium Bioscience, Slate Run Pharma, and Teva Parenteral. and is included in ninety NDAs.
The generic ingredient in ACYCLOVIR is acyclovir sodium. There are fifty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the acyclovir sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acyclovir
A generic version of ACYCLOVIR was approved as acyclovir sodium by FRESENIUS KABI USA on May 13th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACYCLOVIR?
- What are the global sales for ACYCLOVIR?
- What is Average Wholesale Price for ACYCLOVIR?
Summary for ACYCLOVIR
| US Patents: | 0 |
| Applicants: | 61 |
| NDAs: | 90 |
| Finished Product Suppliers / Packagers: | 68 |
| Raw Ingredient (Bulk) Api Vendors: | 185 |
| Clinical Trials: | 130 |
| Patent Applications: | 531 |
| Drug Prices: | Drug price information for ACYCLOVIR |
| Drug Sales Revenues: | Drug sales revenues for ACYCLOVIR |
| What excipients (inactive ingredients) are in ACYCLOVIR? | ACYCLOVIR excipients list |
| DailyMed Link: | ACYCLOVIR at DailyMed |
US Patents and Regulatory Information for ACYCLOVIR
ACYCLOVIR is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting ACYCLOVIR
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lek Pharm | ACYCLOVIR | acyclovir | TABLET;ORAL | 074658-002 | Apr 22, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | ACYCLOVIR SODIUM | acyclovir sodium | INJECTABLE;INJECTION | 215404-001 | Jun 25, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Torrent | ACYCLOVIR | acyclovir | OINTMENT;TOPICAL | 209971-001 | Jan 11, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cipla | ACYCLOVIR | acyclovir | OINTMENT;TOPICAL | 211794-001 | Jan 18, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Yiling | ACYCLOVIR | acyclovir | TABLET;ORAL | 210401-001 | Mar 7, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Parenteral | ACYCLOVIR SODIUM | acyclovir sodium | INJECTABLE;INJECTION | 074969-002 | Aug 26, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
